Next Generation Sequencing Market Overview
The next generation sequencing market size is poised to benefit from a CAGR of 18.05% to reach USD 20,347.45 million by 2025, says Market Research Future (MRFR). Next-generation sequencing technologies are quick procedures that do not necessitate specimen growth in culture. The next-generation sequencing tests allow researchers to detect several infections directly from a sample concurrently.
The intensifying cancer incidence and advancements in cancer treatment are fueling the advancement of the Next Generation Sequencing Market. In addition to these uses, next-generation sequencing is utilized in surveillance testing, forensic genomics, and food microbiology to further global expansion.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/6354
Next Generation Sequencing Market Segmentation
The technology segment consists of whole-genome sequencing, targeted sequencing & resequencing and whole-exome sequencing. The workflow segment consists of sequencing, pre-sequencing, and data analysis. The end user consists of diagnostic laboratories, hospitals & clinics, and pharmaceutical & biotechnology companies. The region consists of the Americas, the Middle East & Africa, Europe, and Asia-Pacific. The application segment consists of oncology, reproductive health, epidemiology & drug development, metagenomics, human leukocyte antigen typing or immune system monitoring, clinical investigation, agrigenomics & forensics, and consumer genomics.
Next Generation Sequencing Market Regional Outlook
During the last five years, the APAC area has drastically lowered the cost of the sequencing technique. The region’s top market participants in the next generation sequencing market are extremely competitive. They offer competitive rates compared to other regions, driving the expansion of the next-generation sequencing industry. Furthermore, the region’s favorable government regulations and lower labor costs are creating good conditions for the growth of the next-generation sequencing business. Europe is expected to have the second-largest market share. The region’s leading market participants are constantly working to develop superior products.
Next Generation Sequencing Market Competitive Landscape
The improving trade relations are projected to increase the international Next Generation Sequencing Market in the coming years. The industry is anticipated to boost as new products are introduced that focus on satisfying the evolving requirements of their respective client bases. Governments worldwide are committing their support for market-friendly changes. The use of the internet for sales and marketing is expected to expand the market’s prospects during the forecast period. The market’s development is projected to be hindered shortly due to a shortage of critical resources. The function of mergers and applications is expected to become critical in maintaining development speed in the coming era. The global contagion has provided businesses with a new mandate about the purchasing process and a rapid acceleration of digital transformation. Fresh business models and perceptions are present in current core operations and support functions in the forecast term. It is projected that implementing comprehensive research techniques to examine the market’s future development will aid in market development.
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/next-generation-sequencing-market-6354
The notable companies in the next generation sequencing market are Agilent Technologies, Inc. (US), Pacific Biosciences of California, Inc. (US), Charles River (US), Eurofins Scientific (Luxembourg), GenScript (US), Illumina, Inc. (US), Thermo Fisher Scientific (US), Qiagen (Germany), PerkinElmer Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Genome Life Sciences (India), Xcelris Genomics (India), Macrogen, Inc. (South Korea), BGI (US), and Oxford Nanopore Technologies (UK).
Haystack Analytics, a health-tech firm, claims to have invented India’s first Universal Infectious Disease (ID) genomic test, making it the world’s first company to provide genomics-based infectious disease diagnostics to hospitals. The test uses Next-Generation Sequencing (NGS) technology to identify existing and developing infections while also providing information on drug resistance to help patients support and discover appropriate treatment alternatives. According to the business, the Universal ID test is a single test solution for accurate and quick infectious illness diagnosis. The tests will be implemented over the following three months in collaboration with hospitals and diagnostic centers around the country, with an initial focus on ICU patients in hospitals.
Browse Related Reports at:
Sterility Testing Market Research Report – Global Forecast till 2027
Cardiac Pacemaker Market Research Report – Global Forecast till 2027
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071